Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18479222rdf:typepubmed:Citationlld:pubmed
pubmed-article:18479222lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:18479222lifeskim:mentionsumls-concept:C0920425lld:lifeskim
pubmed-article:18479222lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:18479222pubmed:issue6lld:pubmed
pubmed-article:18479222pubmed:dateCreated2008-5-15lld:pubmed
pubmed-article:18479222pubmed:abstractTextRecent evidence has established the non receptor tyrosine kinase, Src, as a critical component of multiple signalling pathways that regulate proliferation, survival, angiogenesis and metastasis. Increased levels of Src protein and activity are widely reported in human cancers including breast cancer, and its important role in oncogenic processes makes it a potential target for therapeutic intervention.lld:pubmed
pubmed-article:18479222pubmed:languageenglld:pubmed
pubmed-article:18479222pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18479222pubmed:citationSubsetIMlld:pubmed
pubmed-article:18479222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18479222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18479222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18479222pubmed:statusMEDLINElld:pubmed
pubmed-article:18479222pubmed:monthJunlld:pubmed
pubmed-article:18479222pubmed:issn1744-7631lld:pubmed
pubmed-article:18479222pubmed:authorpubmed-author:NicholsonRobe...lld:pubmed
pubmed-article:18479222pubmed:authorpubmed-author:HiscoxStephen...lld:pubmed
pubmed-article:18479222pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18479222pubmed:volume12lld:pubmed
pubmed-article:18479222pubmed:ownerNLMlld:pubmed
pubmed-article:18479222pubmed:authorsCompleteYlld:pubmed
pubmed-article:18479222pubmed:pagination757-67lld:pubmed
pubmed-article:18479222pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:meshHeadingpubmed-meshheading:18479222...lld:pubmed
pubmed-article:18479222pubmed:year2008lld:pubmed
pubmed-article:18479222pubmed:articleTitleSrc inhibitors in breast cancer therapy.lld:pubmed
pubmed-article:18479222pubmed:affiliationRCUK Academic Fellow Cardiff University, Welsh School of Pharmacy, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3XF, UK. HiscoxSE1@cf.ac.uklld:pubmed
pubmed-article:18479222pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18479222pubmed:publicationTypeReviewlld:pubmed
pubmed-article:18479222pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18479222lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18479222lld:pubmed